Therapeutic Asset Ratings
243 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Monomethyl Fumarate
Lymphoma
National Cancer Institute (NCI)
P3
B
(60)
Palifermin
Lymphoma
Center for International Blood and Marrow Transplant Research
P3
B
(60)
Vinorelbine
Lymphoma
Memorial Sloan Kettering Cancer Center
P3
B
(60)
Nivolumab
Lymphoma
National Cancer Institute (NCI)
P2
B
(60)
Fluconazole
Lymphoma
Hutchmed
P3
B
(59)
Mechlorethamine
Lymphoma
Memorial Sloan Kettering Cancer Center
P3
B
(59)
Clofarabine
Lymphoma
Memorial Sloan Kettering Cancer Center
P2
B
(59)
Peg-Rhg-Csf
Lymphoma
Ou Bai, MD/PHD
P4
B
(58)
Plerixafor
Lymphoma
Peking University
P4
B
(58)
ABATACEPT RECOMBINANT
Lymphoma
Center for International Blood and Marrow Transplant Research
P3
B
(58)
Dexrazoxane
Lymphoma
Beth Israel Deaconess Medical Center
P2
B
(58)
Polatuzumab Vedotin
Lymphoma
Beth Israel Deaconess Medical Center
P2
B
(58)
Tisagenlecleucel
Lymphoma
Beijing Doing Biomedical Co., Ltd.
P2
B
(58)
Ketorolac Tromethamine
Lymphoma
St. Louis University
P3
B
(57)
Tocilizumab
Lymphoma
Hoffmann-La Roche
P3
B
(57)
DARATUMUMAB
Lymphoma
M.D. Anderson Cancer Center
P2
B
(57)
Tazemetostat
Lymphoma
Fudan University
P2
B
(57)
ABRYSVO
Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
P4
B
(56)
Afluria
Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
P4
B
(56)
Fluarix
Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
P4
B
(56)
Flucelvax
Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
P4
B
(56)
Flulaval
Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
P4
B
(56)
Fluzone
Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
P4
B
(56)
Heplisav-B
Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
P4
B
(56)
pcv20
Lymphoma
M.D. Anderson Cancer Center
P4
B
(56)
Showing 51 to 75 of 243 assets
Previous
Page 3 of 10
Next
